FDA Label Restriction Triggers Increased Uptake of PD-L1 Assays in Urothelial Carcinoma
FDA label changes for certain immunotherapies may have prompted a marked increase in the use of PD-L1 assays.
Bladder Cancer
BLADDER CANCER ADVISOR
FEATURED CONTENT
-
-
Thawing Frozen Cancer Drug Labels
As medical care rapidly evolves, there’s really no debate over the potential for drug labels to become outdated, particularly in the high stakes world of cancer treatment. The question is how best to ameliorate the problem, while still protecting the process from financial and other conflicts. Off-label prescribing of cancer drugs is common, occurring 30%… -
Adding Gemcitabine at the Time of Resection Reduces Recurrence, Cost in Early-Stage Bladder Cancer
Though early-stage bladder cancer is infrequently fatal, the decrease in recurrence rates has a meaningful impact on the quality of life for patients as well as treatment costs. -
Muscle-Invasive Bladder Cancer: The Evolving Treatment Landscape
Patients diagnosed with MIBC are at a significant risk for death — which has not greatly improved in the last few decades. -
Bladder Cancer: Immunotherapies, Combination Therapies, and Current Research
Several promising drugs have been approved for the treatment of bladder cancer within the phase year, but combination therapies may be still more effective.
VIDEO SERIES
Immunotherapy for Advanced Bladder Cancer: The Next Frontier
Bladder-sparing Strategies
Intravesical Therapy: When Bacillus Calmette-Guerin Fails
AUA Guidelines: Non-muscle Invasive Bladder Cancer
Bladder Cancer Biomarkers: New and Old
Current Research and New Treatments
PD-L1 Inhibitors Changing the Standard of Care
The Emergence of Personalized Medicine
BLADDER CANCER NEWS
Avelumab Shown to Prolong Survival in Advanced Urothelial Carcinoma
Pembrolizumab Benefits Durable in BCG-Unresponsive High-Risk NMIBC
Prioritizing Urologic Cancer Cases During the COVID-19 Pandemic
Pathologic Stage at RNU Predicts Oncologic Outcomes in High-Grade UTUC
5-ARIs Do Not Lower Bladder Cancer Risk
Want to read more?
Please login or register first to view this content.
Next post in Bladder Cancer
